RNAC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RNAC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cartesian Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-10.50. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-56.10.
Cartesian Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-10.50. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-56.10.
Cartesian Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-2.38. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.13.
During the past 3 years, the average EPS without NRIGrowth Rate was -10.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 42.80% per year.
During the past 10 years, Cartesian Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 72.90% per year. The lowest was -36.90% per year. And the median was 31.90% per year.
The historical data trend for Cartesian Therapeutics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cartesian Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -36.60 | -20.40 | -6.60 | 3.00 | -49.80 |
Cartesian Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -4.24 | -2.10 | -1.80 | -41.70 | -10.50 |
For the Biotechnology subindustry, Cartesian Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Cartesian Therapeutics's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Cartesian Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Diluted Earnings Per Share (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-219.71 | - | 0) | / | 5.170 | |
= | -42.50 |
Cartesian Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as
Diluted Earnings Per Share (Q: Mar. 2024 ) | = | (Net Income | - | Preferred Dividends | / | Shares Outstanding (Diluted Average) |
= | (-56.824 | - | 0) | / | 5.414 | |
= | -10.50 |
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Cartesian Therapeutics (NAS:RNAC) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Cartesian Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Carsten Brunn | director, officer: President & CEO | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Peter G Traber | officer: Chief Medical Officer | 430 THAMER LANE, HOUSTON TX 77025 |
Takashi Kei Kishimoto | officer: Chief Scientific Officer | 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472 |
Lloyd P. Johnston | officer: COO and SVP, R&D | 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472 |
Blaine Davis | officer: Chief Financial Officer | C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014 |
Carrie Smith Cox | director | SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Timothy C Barabe | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Timothy A Springer | director | 36 WOODMAN ROAD, CHESTNUT HILL MA 02467 |
Kevin Tan | officer: Chief Financial Officer | 20 HICKORY ROAD, WELLESLEY MA 02482 |
Nishan M Desilva | director | 11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037 |
Ann K. Donohue | officer: VP Finance | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472 |
Bradford D. Dahms | officer: Chief Financial Officer | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Goran Ando | director | |
Scott Dunseth Myers | director | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Elona Esq. Kogan | officer: General Counsel | C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065 |
From GuruFocus
By sperokesalga sperokesalga • 03-21-2023
By sperokesalga sperokesalga • 05-31-2023
By GuruFocusNews GuruFocusNews • 06-23-2022
By PurpleRose PurpleRose • 07-13-2022
By GuruFocusNews GuruFocusNews • 04-06-2022
By PurpleRose PurpleRose • 08-01-2022
By sperokesalga sperokesalga • 02-23-2023
By Stock market mentor Stock market mentor • 02-07-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By sperokesalga sperokesalga • 04-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.